Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.
1. A method of forming bone in vivo comprising implanting a graft composition comprising collagen or hydrogel matrix and tacrolimus in the absence of a growth factor in a subject such that bone forms in the graft.
2. The method of claim 1 , wherein more than 0.7 mg of tacrolimus is present per 150 mm 3 of bone graft volume.
3. The method of claim 1 , wherein the bone graft further comprises calcium phosphates.
4. The method of claim 3 , wherein said calcium phosphates are hydroxyapatite and tricalcium phosphate.